Updated Results of APHINITY at 8.4 Years Median Follow Up

Dr Sara M Tolaney reviews data from the APHINITY trial regarding the pertuzumab plus trastuzumab and chemotherapy treatment regimen for patients with HER2+ breast cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    x